Park Avenue Securities’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-59,915
| Closed | -$242K | – | 1485 |
|
|
2025
Q1 | $242K | Hold |
59,915
| – | – | ﹤0.01% | 1074 |
|
|
2024
Q4 | $192K | Hold |
59,915
| – | – | ﹤0.01% | 1436 |
|
|
2024
Q3 | $134K | Hold |
59,915
| – | – | ﹤0.01% | 1353 |
|
|
2024
Q2 | $129K | Hold |
59,915
| – | – | ﹤0.01% | 1338 |
|
|
2024
Q1 | $123K | Sell |
59,915
-17
| -0% | -$34 | ﹤0.01% | 1341 |
|
|
2023
Q4 | $137K | Hold |
59,932
| – | – | ﹤0.01% | 1315 |
|
|
2023
Q3 | $102K | Buy |
+59,932
| New | +$136K | ﹤0.01% | 1241 |
|
|
2023
Q1 | – | Sell |
-46,545
| Closed | -$238K | – | 778 |
|
|
2022
Q4 | $238K | Buy |
46,545
+35,527
| +322% | +$256K | ﹤0.01% | 1070 |
|
|
2022
Q3 | $115K | Hold |
11,018
| – | – | ﹤0.01% | 1087 |
|
|
2022
Q2 | $113K | Sell |
11,018
-10,000
| -48% | -$131K | ﹤0.01% | 1097 |
|
|
2022
Q1 | $372K | Buy |
21,018
+15,618
| +289% | +$335K | 0.01% | 867 |
|
|
2021
Q4 | $168K | Hold |
5,400
| – | – | ﹤0.01% | 1079 |
|
|
2021
Q3 | $178K | Hold |
5,400
| – | – | ﹤0.01% | 1010 |
|
|
2021
Q2 | $159K | Hold |
5,400
| – | – | ﹤0.01% | 999 |
|
|
2021
Q1 | $170K | Buy |
5,400
+17
| +0.3% | +$570 | ﹤0.01% | 931 |
|
|
2020
Q4 | $143K | Hold |
5,383
| – | – | ﹤0.01% | 831 |
|
|
2020
Q3 | $144K | Hold |
5,383
| – | – | ﹤0.01% | 719 |
|
|
2020
Q2 | $107K | Buy |
+5,383
| New | +$98.1K | ﹤0.01% | 669 |
|
|
2020
Q1 | – | Sell |
-5,383
| Closed | -$93K | – | 340 |
|
|
2019
Q4 | $93K | Hold |
5,383
| – | – | ﹤0.01% | 601 |
|
|
2019
Q3 | $134K | Buy |
+5,383
| New | +$148K | 0.01% | 516 |
|
|
2019
Q2 | – | Sell |
-6,659
| Closed | -$199K | – | 287 |
|
|
2019
Q1 | $199K | Buy |
+6,659
| New | +$213K | 0.01% | 448 |
|
Park Avenue Securities's CKPT Position: Q2 2025 in Review
Park Avenue Securities sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 59,915 shares — an estimated $242K sold.
Park Avenue Securities first reported a position in CKPT in Q1 2019 and held it in 21 quarters. The position peaked at $372K in Q1 2022. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Park Avenue Securities reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Park Avenue Securities sold 59,915 Checkpoint Therapeutics shares in Q2 2025, an estimated $242K.
- Park Avenue Securities first reported a position in Checkpoint Therapeutics in Q1 2019 and held it in 21 quarters.
- Park Avenue Securities's Checkpoint Therapeutics position peaked at $372K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Park Avenue Securities's 13F filing for Q2 2025, filed 14 Jul 2025.